Trinity Biotech Plc Stock Analysis

Trinity Stock Analysis Notes

About 12.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 1.3. Trinity Biotech plc recorded a loss per share of 1.8. The entity last dividend was issued on the 5th of June 2015. The firm had 1:5 split on the 23rd of February 2024. Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the Americas, Africa, Asia, and Europe. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Trinity Bio operates under Pharmaceuticals And Biosciences classification in the United States and is traded on NASDAQ Exchange. It employs 477 people. To find out more about Trinity Biotech plc contact Aris Kekedjian at 353 1 276 9800 or learn more at https://www.trinitybiotech.com.

Trinity Biotech plc Investment Alerts

Trinity Largest EPS Surprises

View All Earnings Estimates

Trinity Stock Institutional Investors

Note, although Trinity Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Trinity Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.89 M.

Trinity Profitablity

The company has Profit Margin (PM) of (0.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.43) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.43.

Management Efficiency

Trinity Biotech plc has return on total asset (ROA) of (0.1053) % which means that it has lost $0.1053 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.1345) %, meaning that it created substantial loss on money invested by shareholders. Trinity Biotech's management efficiency ratios could be used to measure how well Trinity Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.85, whereas Return On Tangible Assets are projected to grow to (0.67). At present, Trinity Biotech's Total Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 72.7 M, whereas Non Currrent Assets Other are forecasted to decline to about 165.9 K.

Technical Drivers

As of the 15th of February 2026, Trinity Biotech has the Coefficient Of Variation of 88492.12, semi deviation of 5.43, and Risk Adjusted Performance of 0.0099. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Trinity Biotech plc, as well as the relationship between them.

Trinity Biotech plc Price Movement Analysis

Trinity Biotech plc Insider Trading Activities

Trinity Biotech Outstanding Bonds

Trinity Biotech Predictive Daily Indicators

Trinity Biotech Forecast Models

Trinity Biotech's time-series forecasting models are one of many Trinity Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Trinity Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Trinity Biotech Bond Ratings

Trinity Biotech plc financial ratings play a critical role in determining how much Trinity Biotech have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Trinity Biotech's borrowing costs.

Trinity Biotech plc Debt to Cash Allocation

Trinity Biotech plc currently holds 100.76 M in liabilities. Trinity Biotech plc has a current ratio of 3.59, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Trinity Biotech's use of debt, we should always consider it together with its cash and equity.

Trinity Biotech Total Assets Over Time

Trinity Biotech Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Trinity Biotech uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Trinity Biotech Debt Ratio

92.0

It appears most of the Trinity Biotech's assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Trinity Biotech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Trinity Biotech, which in turn will lower the firm's financial flexibility.

Trinity Biotech Corporate Bonds Issued

Trinity Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Trinity Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Trinity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Trinity Biotech. By using and applying Trinity Stock analysis, traders can create a robust methodology for identifying Trinity entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Trinity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Trinity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Trinity Biotech plc stock analysis indicators help investors evaluate how Trinity Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Trinity Biotech shares will generate the highest return on investment. By understating and applying Trinity Biotech stock analysis, traders can identify Trinity Biotech position entry and exit signals to maximize returns.

When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.